What are the key takeaways from this Beyond Biotech episode?

Key insights include: **CCR8 Treg depletion mechanism:** DT-7012 targets CCR8 to deplete T regulatory cells from the tumor microenvironment, restoring immune competitiveness against tumors. The Phase 1 trial in Australia has already confirmed Treg depletion in blood; the critical paired biopsy data confirming depletion within the tumor microenvironment itself is expected late Q2 or early Q3 2025.; **GPCR platform differentiation:** Unlike competing platforms that require locking the GPCR into a fixed configuration, Kynova's platform works with the native receptor. This enables discovery of allosteric modulators beyond standard antagonists, and allows measurement of downstream signaling — expanding viable targets into immuno-oncology and inflammation rather than only CNS and cardiometabolic areas.; **Biotech-scale pivotal trial design:** When selecting an indication for a pivotal trial, size the approvable dataset to be VC-fundable and choose indications with concentrated prescriber bases addressable by a biotech-scale salesforce. Kynova applied this framework to identify a path toward accelerated approval for DT-7012 before 2030, while still fitting within the pharma patent cliff window.

What did Next-gen Gpcr Modulation discuss on Beyond Biotech?

Sean Mac, CEO of Kynova Therapeutics, outlines the company's GPCR-based drug discovery platform, its lead anti-CCR8 antibody DT-7012 in Phase 1, a $32M Series B raise, and the strategic rebrand from Domain Therapeutics as the company targets immuno-oncology and inflammation. Key topics include: **CCR8 Treg depletion mechanism:** DT-7012 targets CCR8 to deplete T regulatory cells from the tumor microenvironment, restoring immune competitiveness against tumors. The Phase 1 trial in Australia has already confirmed Treg depletion in blood; the critical paired biopsy data confirming depletion within the tumor microenvironment itself is expected late Q2 or early Q3 2025.; **GPCR platform differentiation:** Unlike competing platforms that require locking the GPCR into a fixed configuration, Kynova's platform works with the native receptor. This enables discovery of allosteric modulators beyond standard antagonists, and allows measurement of downstream signaling — expanding viable targets into immuno-oncology and inflammation rather than only CNS and cardiometabolic areas..

How long is this episode of Beyond Biotech?

This episode is 34 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Beyond Biotech

Reversing tumor immunosuppression with next-gen GPCR modulation

March 6, 2026

34 min episode · 2 min read

Next-gen Gpcr Modulation

Episode

34 min

Read time

2 min

Topics

Relationships, Fundraising & VC, Leadership

AI-Generated Summary

Published Mar 13, 2026

Key Takeaways

✓CCR8 Treg depletion mechanism: DT-7012 targets CCR8 to deplete T regulatory cells from the tumor microenvironment, restoring immune competitiveness against tumors. The Phase 1 trial in Australia has already confirmed Treg depletion in blood; the critical paired biopsy data confirming depletion within the tumor microenvironment itself is expected late Q2 or early Q3 2025.
✓GPCR platform differentiation: Unlike competing platforms that require locking the GPCR into a fixed configuration, Kynova's platform works with the native receptor. This enables discovery of allosteric modulators beyond standard antagonists, and allows measurement of downstream signaling — expanding viable targets into immuno-oncology and inflammation rather than only CNS and cardiometabolic areas.
✓Biotech-scale pivotal trial design: When selecting an indication for a pivotal trial, size the approvable dataset to be VC-fundable and choose indications with concentrated prescriber bases addressable by a biotech-scale salesforce. Kynova applied this framework to identify a path toward accelerated approval for DT-7012 before 2030, while still fitting within the pharma patent cliff window.
✓Mid-size pharma as deal targets: Beyond top-15 pharma, a growing tier of mid-size companies that have commercialized their first products now face the same pipeline renewal pressures. These players pursue deals in the $1–3B range, creating a broader M&A market that biotech companies should actively target alongside traditional large-pharma partnership conversations.
✓Non-dilutive capital sequencing: Securing a strong cash position first makes accessing non-dilutive capital significantly easier. Kynova pursues platform licensing deals and asset transactions alongside equity rounds, using incoming non-dilutive funds to extend runway and reduce reliance on Series C timing — a sequencing strategy applicable to any early-stage biotech managing cash between clinical milestones.

What It Covers

Sean Mac, CEO of Kynova Therapeutics, outlines the company's GPCR-based drug discovery platform, its lead anti-CCR8 antibody DT-7012 in Phase 1, a $32M Series B raise, and the strategic rebrand from Domain Therapeutics as the company targets immuno-oncology and inflammation.

Key Questions Answered

•CCR8 Treg depletion mechanism: DT-7012 targets CCR8 to deplete T regulatory cells from the tumor microenvironment, restoring immune competitiveness against tumors. The Phase 1 trial in Australia has already confirmed Treg depletion in blood; the critical paired biopsy data confirming depletion within the tumor microenvironment itself is expected late Q2 or early Q3 2025.
•GPCR platform differentiation: Unlike competing platforms that require locking the GPCR into a fixed configuration, Kynova's platform works with the native receptor. This enables discovery of allosteric modulators beyond standard antagonists, and allows measurement of downstream signaling — expanding viable targets into immuno-oncology and inflammation rather than only CNS and cardiometabolic areas.
•Biotech-scale pivotal trial design: When selecting an indication for a pivotal trial, size the approvable dataset to be VC-fundable and choose indications with concentrated prescriber bases addressable by a biotech-scale salesforce. Kynova applied this framework to identify a path toward accelerated approval for DT-7012 before 2030, while still fitting within the pharma patent cliff window.
•Mid-size pharma as deal targets: Beyond top-15 pharma, a growing tier of mid-size companies that have commercialized their first products now face the same pipeline renewal pressures. These players pursue deals in the $1–3B range, creating a broader M&A market that biotech companies should actively target alongside traditional large-pharma partnership conversations.
•Non-dilutive capital sequencing: Securing a strong cash position first makes accessing non-dilutive capital significantly easier. Kynova pursues platform licensing deals and asset transactions alongside equity rounds, using incoming non-dilutive funds to extend runway and reduce reliance on Series C timing — a sequencing strategy applicable to any early-stage biotech managing cash between clinical milestones.

Notable Moment

Sean Mac described how Kynova's EP4 receptor program DT-9081 completed Phase 1 but was deliberately moved to an investigator-sponsored trial rather than funded by the Series B — because VC appetite for combination immuno-oncology trials remains limited, despite the mechanism showing clear relevance to cancer resistance.

Know someone who'd find this useful?

Episode Transcript

Hello, and welcome to Beyond Biotech, the weekly podcast from Le BioTech. I'm Dylan Kysain, and this is episode 187 for the podcast. Today, we're joined by Sean McDonald, CEO of Kynova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter. We'll dive into Kynova's innovative g p c r modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from domain therapeutics to Kynova therapeutics. We'll also be taking a look at the broader oncology landscape, what's hot, who's investing big, and where the biggest opportunities and challenges lie. I hope you enjoy my conversation with Sean McDonald. Sean, welcome to Beyond Biotech. Thank you for the opportunity. Sean, why don't you walk us through your journey in biotech? What was it that really first sparked your interest early on? That's a a a great question. I I think that, to be perfectly honest, it goes back to my high school days. I had a very successful sister who was on the business side, and I didn't want to be compared at the Loveline parents. So that was what initially drove me into science. And it turned out I really enjoyed it. I had great chemistry teacher, great biology teacher, and that's what really kind of pushed me towards that as I moved into university. I think ultimately what kind of led me more onto the business side was I realized that micropipetting was not my future. And so I was looking for alternatives of how to use my molecular biology degree, which didn't require me to carry on, do a PhD in a couple of postdocs before I was ready to be employable. And so ended up working with a couple of friends on some business plans for some university profs and went back, did an MBA market research, business development, and it really was kind of in business development that you get a lot of, you know, particularly working for small biotechs, a lot of access to strategy and know, product development and, you know, these these types of items and, you know, ultimately led me to the role that I'm in today. Tell me a little bit more about this career though, because it's been more than twenty years since you Yep. Came out of that study there. What sort of roles have you held along the way? Sure. So I got my very first, I would say, in the true industrial start. You know, because I I mentioned I hooked up with a couple of friends and we were doing business plans and things, and that's because we actually created our own consulting business. But, I realized relatively quickly that your mid twenties is not necessarily the right time to be a industry consultant. Certainly didn't have enough gray hair at the time, and ended up in …

Get the full transcript (5,587 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Beyond Biotech transcripts →